The use of erythropoietin in gynecologic cancer patients

dc.contributor.author	Κουρούνης, Γεώργιος	el
dc.contributor.author	Ιατράκης, Γεώργιος Μ.	el
dc.contributor.author	Χρονόπουλος, Κ.	el
dc.contributor.author	Λιάτσος, Κωνσταντίνος	el
dc.contributor.author	Λαδόπουλος, Ιωάννης	el
dc.date.accessioned	2015-05-13T17:43:59Z
dc.date.issued	2015-05-13
dc.identifier.uri	http://hdl.handle.net/11400/10321
dc.rights	Αναφορά Δημιουργού-Μη Εμπορική Χρήση-Όχι Παράγωγα Έργα 3.0 Ηνωμένες Πολιτείες	*
dc.rights.uri	http://creativecommons.org/licenses/by-nc-nd/3.0/us/	*
dc.source	http://www.irog.net/ejgo	en
dc.source	http://www.ncbi.nlm.nih.gov/pubmed/15597854	en
dc.subject	Oncology
dc.subject	Cancer
dc.subject	Hormones
dc.subject	Ογκολογία
dc.subject	Καρκίνος
dc.subject	Ορμόνες
dc.subject	Ερυθροποιητίνη
dc.title	The use of erythropoietin in gynecologic cancer patients	en
heal.type	journalArticle
heal.classification	Medicine
heal.classification	Gynecology
heal.classification	Ιατρική
heal.classification	Γυναικολογία
heal.classificationURI	http://id.loc.gov/authorities/subjects/sh00006614
heal.classificationURI	http://id.loc.gov/authorities/subjects/sh85058092
heal.classificationURI	N/A-Ιατρική
heal.classificationURI	N/A-Γυναικολογία
heal.keywordURI	http://skos.um.es/unesco6/320713
heal.dateAvailable	10000-01-01
heal.language	en
heal.access	forever
heal.recordProvider	Σχολή Επαγγελμάτων Υγείας και Πρόνοιας. Τμήμα Μαιευτικής	el
heal.publicationDate	2004
heal.bibliographicCitation	Kourounis, G., Iatrakis, G., Chronopoulos, K., Liatsos, K. and Ladopoulos, I. (2004) The use of erythropoietin in gynecologic cancer patients. "European Journal of Gynaecological Oncology", 25 (6), p. 735-736. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15597854 [Accessed: 13/05/2015].	en
heal.abstract	PURPOSE: To investigate the possible benefits of erythroproietin ingestion in patients with various gynecological cancers with proven severe iron deficiency anemia. METHOD: Seven patients with gynecological cancer were included in the study. Nadir hematocrit values were found to be 20-24% before the initiation of recombinant human erythropoietin treatment. Initial therapy started at 50 units/kg/dose, three times weekly for a month. The dose was modified according to the rise of hemoglobin after a month's period. The dose was modified according to the rise of hemoglobin after a month's period. If the rise was greater than 2 g/dl the dose was changed to 25 units/kg two times weekly and if it was less than 2 g/dl it was changed to 25 units/kg three times weekly per month. Five patients were simultaneously given erythropoietin therapy and iron supplementation. RESULTS: We confirmed a rise in the hematocrit values which averaged 0.5-1.5% weekly till the upper limit. Reticulocyte and hematocrit values were higher in the erythropoietin plus iron group (five cases). CONCLUSION: In this small series, erythropoietin appeared to be effective in treating severe iron deficiency in gynecologic cancer patients. Further investigation is needed to confirm these results.	en
heal.publisher	Marchetti, M.	el
heal.journalName	European Journal of Gynaecological Oncology	en
heal.journalType	peer-reviewed
heal.fullTextAvailability	false